DENPOZIN-M
Description_Effects
DENPOZIN-M is an advanced combination therapy used for the management of type 2 diabetes mellitus in adults. It combines Dapagliflozin, Metformin, and Sitagliptin, three well-established antidiabetic agents that work through complementary mechanisms to effectively control blood sugar levels, especially in patients who do not achieve adequate glycemic control with monotherapy or dual therapy. Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor that reduces blood sugar by preventing the kidneys from reabsorbing glucose, thereby promoting its excretion through urine. This not only lowers blood glucose but may also assist in weight management and blood pressure reduction. Metformin is a first-line biguanide antidiabetic agent that reduces hepatic glucose production and improves insulin sensitivity. It also limits intestinal glucose absorption, resulting in better post-meal blood sugar control. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by increasing the levels of incretin hormones, which help the body produce more insulin and reduce the production of glucose in the liver when blood sugar is high. DENPOZIN-M is typically taken once or twice daily with meals to reduce gastrointestinal side effects. This combination helps maintain stable blood sugar levels, reduces the risk of complications, and supports overall metabolic health when combined with a healthy diet and regular physical activity.
